https://www.ophthalmologytimes.com/view/fda-approves-clobetasol-propionate-ophthalmic-suspension-0-05-from-formosa-pharmaceuticals-and-aimmax-therapeutics 2024-03-05 0.50 https://www.ophthalmologytimes.com/view/cophy-2024-facing-the-controversies-in-ophthalmology-face-to-face 2024-03-04 0.50 https://www.ophthalmologytimes.com/view/fortifeye-launches-eye-pressure-and-neuro-cognitive-support-supplement 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/cu-ophthalmology-residents-employ-portable-fundus-photography-cameras-to-enhance-on-call-imaging 2024-03-04 0.50 https://www.ophthalmologytimes.com/view/pulsesight-therapeutics-launches-to-advance-non-viral-gene-therapies-for-severe-retinal-diseases 2024-02-29 0.50 https://www.ophthalmologytimes.com/view/an-ophthalmologist-with-personal-experience-has-explored-the-impact-of-ai-driven-solutions 2024-02-29 0.50 https://www.ophthalmologytimes.com/view/potential-treatments-for-lowe-syndrome-with-previously-fda-approved-therapies 2024-02-29 0.50 https://www.ophthalmologytimes.com/view/rare-disease-day-ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-1-in-phase-1-2-trial-of-ocu410st 2024-02-29 0.50 https://www.ophthalmologytimes.com/view/vision-related-quality-of-life-in-patients-with-rvo 2024-02-28 0.50 https://www.ophthalmologytimes.com/view/translocated-gut-bacteria-possible-cause-of-some-inherited-eye-diseases 2024-02-27 0.50 https://www.ophthalmologytimes.com/view/optos-marks-25-000-devices-installed-globally 2024-02-27 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-announces-updates-to-leadership-board-of-directors 2024-02-26 0.50 https://www.ophthalmologytimes.com/view/managing-expectations-of-referring-doctors-and-patient-after-retinal-detachment-repair 2024-02-23 0.50 https://www.ophthalmologytimes.com/view/overcoming-health-disparities-in-diabetic-retinopathy 2024-02-26 0.50 https://www.ophthalmologytimes.com/view/retinal-vascular-abnormalities-may-be-surrogate-biomarkers-of-alzheimer-s-disease-before-symptom-onset 2024-02-22 0.50 https://www.ophthalmologytimes.com/view/jcyte-inc-announces-pivotal-trial-of-jcell-for-rp-to-start-in-second-half-of-2024 2024-02-22 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-launches-new-retinopathy-of-prematurity-education-and-support-program-as-part-of-inaugural-rop-awareness-week 2024-02-22 0.50 https://www.ophthalmologytimes.com/view/structural-and-vascular-changes-detected-in-rvo-affected-eyes-and-unaffected-fellow-eyes 2024-02-22 0.50 https://www.ophthalmologytimes.com/view/ai-surprising-proficiency-in-retina-and-glaucoma-management 2024-02-22 0.50 https://www.ophthalmologytimes.com/view/reatment-developed-to-dramatically-slow-progression-of-blindness-causing-retinal-disease 2024-02-20 0.50 https://www.ophthalmologytimes.com/view/physical-activity-in-older-adults-with-visual-impairment-increased-by-improved-home-lighting 2024-02-20 0.50 https://www.ophthalmologytimes.com/view/retinai-debuts-discovery-platform-to-boost-ophthalmic-care 2024-02-20 0.50 https://www.ophthalmologytimes.com/view/envision-summit-2024-using-the-micor-700-device-for-phacoemulsification-cataract-surgery 2026-04-03 0.50 https://www.ophthalmologytimes.com/view/washington-university-researcher-receives-300-000-grant-to-study-amd 2024-02-20 0.50 https://www.ophthalmologytimes.com/view/harrow-announces-licensing-agreement-with-apotex-to-market-5-ophthalmic-products-in-canada 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/consensus-guidelines-on-ga-diagnosis-and-management 2024-02-20 0.50 https://www.ophthalmologytimes.com/view/current-management-and-prevention-of-vitreoretinal-complications-of-high-myopia 2024-02-19 0.50 https://www.ophthalmologytimes.com/view/changing-the-game-the-one-minute-eye-exam 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/envision-summit-2024-the-case-of-a-highly-contagious-inherited-retinal-disease 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/envision-summit-2024-leadership-talk-guides-women-in-eye-care-through-personal-ipo-journey 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/envision-summit-2024-inside-the-new-optometry-program-and-glaucoma-panel 2024-02-15 0.50 https://www.ophthalmologytimes.com/view/groups-new-prior-authorization-rule-could-reduce-physicians-burden-improve-patient-care 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-to-host-webinar-offering-best-practices-for-managing-patients-diagnosed-with-inherited-retinal-diseases 2024-02-14 0.50 https://www.ophthalmologytimes.com/view/eyebio-announces-positive-data-from-first-in-human-ph1b-2a-amarone-trial-of-restoret-for-dme-dvamd 2024-02-14 0.50 https://www.ophthalmologytimes.com/view/fda-approves-eyenovia-s-redwood-city-commercial-manufacturing-facility 2024-02-14 0.50 https://www.ophthalmologytimes.com/view/novel-protocol-to-rapidly-diagnose-and-treat-retinal-artery-occlusion 2024-02-14 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-inc-screens-and-doses-the-first-3-subjects-in-the-phase-3-sol-1-clinical-trial 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-rolls-out-gyros-study-of-gyrate-atrophy 2024-02-12 0.50 https://www.ophthalmologytimes.com/view/study-new-monitoring-option-for-rare-eye-disease 2024-02-12 0.50 https://www.ophthalmologytimes.com/view/envision-summit-offers-innovation-in-family-friendly-format 2024-02-12 0.50 https://www.ophthalmologytimes.com/view/potential-functional-biomarker-for-early-intermediate-amd-identified-by-alstar-study 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/kyowa-kirin-enrolls-first-patient-in-phase-2-trial-of-drops-for-treatment-of-diabetic-macular-edema 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-releases-positive-preliminary-efficacy-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/fda-gives-ind-clearance-to-okyo-pharma-for-ok-101-in-neuropathic-corneal-pain 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/gaps-in-vision-screening-for-school-aged-children-uncovered-in-study 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-examines-the-influence-of-the-cellular-environment-on-vision 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/ucl-and-moorfields-eye-hospital-receive-5-million-investment-toward-oriel 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-announces-pricing-of-15-million-registered-direct-offering 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/toku-obtains-ce-and-ukca-marks-for-ai-cardiovascular-risk-assessments-through-the-eye 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-releases-12-month-data-from-phase-2-skyline-trial-of-agtc-501-for-patients-with-x-linked-retinitis-pigmentosa 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/4dmt-presents-positive-interim-data-from-phase-2-prism-clinical-trial-of-intravitreal-4d-150-for-wet-amd 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/study-retinal-photoreceptors-use-dual-pathways-to-tell-brain-i-ve-seen-the-light- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/carl-zeiss-meditec-ag-reaches-settlement-with-topcon 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aviceda-begins-part-2-of-phase-ii-iii-trial-for-geographic-atrophy 2024-02-08 0.50 https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-announces-strategic-partnership-with-th-a-open-innovation 2024-02-07 0.50 https://www.ophthalmologytimes.com/view/fda-warns-consumers-of-contaminated-copycat-eye-drops 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/new-long-term-data-for-roche-s-vabysmo-show-sustained-retinal-drying-and-vision-improvements-in-retinal-vein-occlusion 2024-02-07 0.50 https://www.ophthalmologytimes.com/view/mapping-the-specific-progressing-anatomic-features-from-drusen-to-type-3-mnv 2024-02-07 0.50 https://www.ophthalmologytimes.com/view/arvo-awards-2024-carl-camras-translational-research-award 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/all_aboard-app-assists-blind-and-visually-impaired-commuters-in-finding-bus-stops 2024-01-31 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-interim-results-from-the-first-in-human-phase-2-ripple-1-trial-of-a-dexamethasone-implant-for-dme-and-rvo 2024-02-02 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-highlighting-72-week-results-from-the-balaton-and-comino-phase-3-studies-of-faricimab-in-rvo 2024-02-02 0.50 https://www.ophthalmologytimes.com/view/voyager-study-real-world-effectiveness-of-faricimab-for-namd-and-dme 2024-02-01 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-targeting-ang2-and-vegf-the-latest-clinical-data-in-namd-and-dme 2024-02-06 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-utilizing-longitudinal-ai-based-fluid-quantification-for-at-home-monitoring 2024-02-06 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-topline-and-subgroup-analysis-of-the-davio-2-trial-results-assessing-eyp-1901-vs-aflibercept-for-wet-amd 2024-02-06 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-expanded-efficacy-data-from-the-gather-2-trial 2024-02-01 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2024-distinguishing-aspects-of-early-onset-amd 2024-02-01 0.50 https://www.ophthalmologytimes.com/view/multimodal-imaging-an-added-perspective-on-amd-progression 2024-01-29 0.50 https://www.ophthalmologytimes.com/view/inadequate-number-of-ophthalmologic-clinicians-predicted-by-2035 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/researcher-red-light-myopia-therapy-can-injure-retina 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/kodiak-sciences-to-share-first-time-results-of-ksi-501abc-phase-1-study-during-virtual-angiogenesis-exudation-and-degeneration-2024 2024-01-31 0.50 https://www.ophthalmologytimes.com/view/formosa-pharmaceuticals-unveils-licensing-agreement-with-crist-lia-for-commercialization-of-app13007-for-treatment-of-pain-and-inflammation-after-ocular-surgery 2024-01-31 0.50 https://www.ophthalmologytimes.com/view/new-company-formed-to-develop-ascendis-pharma-ophthalmology-assets 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/reginald-sanders-md-fasrs-named-president-of-the-american-society-of-retina-specialists 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oct-predicts-eye-heart-lung-metabolic-neuropsychiatric-diseases 2024-01-26 0.50 https://www.ophthalmologytimes.com/view/artificial-retina-production-planned-for-the-international-space-station 2024-01-29 0.50 https://www.ophthalmologytimes.com/view/ascidian-therapeutics-announces-first-ever-ind-for-an-rna-exon-editor-as-fda-approves-trial-plan-and-fast-tracks-acdn-01-in-stargardt-disease 2024-01-25 0.50 https://www.ophthalmologytimes.com/view/afternoon-sessions-angiogenesis-exudation-and-degeneration-2024-conference-topics-covered 2024-01-26 0.50 https://www.ophthalmologytimes.com/view/retina-fellows-forum-do-you-live-to-work-or-work-to-live- 2024-01-30 0.50 https://www.ophthalmologytimes.com/view/study-ai-driven-eye-exams-boost-screening-rates-for-youth-with-diabetes 2024-01-25 0.50 https://www.ophthalmologytimes.com/view/the-21st-annual-angiogenesis-exudation-and-degeneration-2024-conference-a-1-day-virtual-event-of-all-things-retina 2024-01-26 0.50 https://www.ophthalmologytimes.com/view/double-trouble-handling-retinal-detachment-in-the-setting-of-global-trauma 2024-01-26 0.50 https://www.ophthalmologytimes.com/view/retina-fellows-forum-emerging-therapies-for-amd 2024-01-26 0.50 https://www.ophthalmologytimes.com/view/surgical-video-panels-from-retina-fellows-forum 2024-01-25 0.50 https://www.ophthalmologytimes.com/view/new-virtual-reality-visual-field-analyzer-and-vision-screener-now-available-in-us-ophthalmic-market 2024-01-29 0.50 https://www.ophthalmologytimes.com/view/very-low-incidence-of-ocular-inflammatory-events-reported-after-covid-19-vaccinations-in-the-uk 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/predicting-systemic-diseases-from-ocular-fundus-images 2024-01-26 0.50 https://www.ophthalmologytimes.com/view/sparingvision-reaches-final-dose-escalation-step-in-prodygy-trial-with-spvn06-for-retinitis-pigmentosa 2024-01-25 0.50 https://www.ophthalmologytimes.com/view/tilak-healthcare-announces-positive-results-from-til002-clinical-trial-evaluating-odysight-mobile-app 2024-01-23 0.50 https://www.ophthalmologytimes.com/view/coherus-to-divest-ophthalmology-franchise-to-sandoz-for-170-million 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/feasibility-of-intra-anterior-chamber-anti-vegf-injections-to-treat-advanced-pediatric-vitreoretinal-diseases 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/first-workshop-on-brain-based-vision-disorder-hosted-by-nei 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/iuvo-bioscience-acquires-promedica-international 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-inflammasome-inhibitor-drug-in-subjects-with-dme 2024-01-22 0.50 https://www.ophthalmologytimes.com/view/regenexbio-announces-positive-interim-data-from-phase-ii-aaviate-trial-of-abbv-rgx-314-for-treatment-of-wet-amd 2024-01-19 0.50 https://www.ophthalmologytimes.com/view/rg6501-phase-1-2a-results-will-be-featured-at-2024-angiogenesis-exudation-and-degeneration-meeting 2024-01-19 0.50 https://www.ophthalmologytimes.com/view/new-hampshire-legislators-consider-bill-to-expand-scope-of-optometrists-in-state 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/nighttime-outdoor-artificial-light-may-increase-risk-of-age-related-macular-degeneration 2024-01-19 0.50 https://www.ophthalmologytimes.com/view/tarsier-pharma-receives-fda-agreement-under-special-protocol-assessment-for-tarsier-04-phase-3-trial 2024-01-19 0.50 https://www.ophthalmologytimes.com/view/arpa-h-rolls-out-research-program-to-restore-vision-to-blind-patients 2024-01-18 0.50 https://www.ophthalmologytimes.com/view/orbis-international-nidek-teaming-up-to-scale-up-artificial-intelligence-eye-sceenings-in-vietnam 2024-01-18 0.50 https://www.ophthalmologytimes.com/view/pulsar-phase-3-trial-96-week-results-robust-treatment-response-with-aflibercept-for-namd 2024-01-15 0.50 https://www.ophthalmologytimes.com/view/imaging-features-that-predict-a-treatment-response-in-retinal-vascular-diseases 2024-01-11 0.50 https://www.ophthalmologytimes.com/view/ocular-gene-therapy-the-good-the-bad-and-the-maybe 2024-01-15 0.50 https://www.ophthalmologytimes.com/view/fda-grants-rare-pediatric-disease-rpd-designation-to-atsena-therapeutics-atsn-101-for-leber-congenital-amaurosis 2024-01-16 0.50 https://www.ophthalmologytimes.com/view/oculenz-headset-showcased-at-ces-2024-and-available-for-pre-order-as-visual-aid-for-amd 2024-01-16 0.50 https://www.ophthalmologytimes.com/view/pursuant-health-received-510-k-clearance-from-fda-for-kiosk-offering-self-service-retinal-imaging 2024-01-15 0.50 https://www.ophthalmologytimes.com/view/jane-c-edmond-md-starts-term-as-2024-president-of-aao 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/regenxbio-announces-presentation-at-hawaiian-eye-and-retina 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-ai-driven-eye-exams-increase-screening-rates-for-youth-with-diabetes 2024-01-12 0.50 https://www.ophthalmologytimes.com/view/aviceda-therapeutics-enrolls-the-first-patient-in-glyco-phase-2-of-avd-104-for-dme 2024-01-11 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-doses-first-patient-in-phase-2-verona-clinical-trial-of-eyp-1901-for-treatment-of-dme 2024-01-10 0.50 https://www.ophthalmologytimes.com/view/alkeus-pharmaceuticals-offers-positive-interim-data-showing-gildeuretinol-halted-stargardt-disease-progression 2024-01-10 0.50 https://www.ophthalmologytimes.com/view/gentex-announces-esight-acquisition-will-showcase-vision-technology-at-ces-2024 2024-01-09 0.50 https://www.ophthalmologytimes.com/view/acetylcholinesterase-inhibitors-associated-with-lower-risk-of-amd-in-alzheimer-disease-patients 2024-01-09 0.50 https://www.ophthalmologytimes.com/view/annexon-outlines-2024-strategy-for-anx007-for-geographic-atrophy 2024-01-09 0.50 https://www.ophthalmologytimes.com/view/european-commission-grants-eu-marketing-authorization-for-aflibercept-eylea-8-mg 2024-01-08 0.50 https://www.ophthalmologytimes.com/view/4dmt-shares-pipeline-progress-and-the-appointment-of-new-cso-and-sab-board-members 2024-01-08 0.50 https://www.ophthalmologytimes.com/view/cognition-therapeutics-ceo-shares-update-on-magnify-trial-enrollment-and-the-company-s-work-on-dry-amd 2024-01-05 0.50 https://www.ophthalmologytimes.com/view/aldeyra-therapeutics-announces-anticipated-submission-of-ind-application-for-rasp-modulator-adx-248-in-patients-with-dry-amd 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/focus-on-the-retina-program-2024-in-the-tropics 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/hawaiian-eye-and-retina-meeting-comprehensive-meeting-in-a-setting-beyond-compare 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/ascend-vision-partners-avp-forms-partnership-with-bay-area-retina-consultants 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/alimera-sciences-completes-enrollment-in-phase-4-synchronicity-study 2024-01-05 0.50 https://www.ophthalmologytimes.com/view/fda-issues-revised-draft-guidance-on-quality-considerations-for-ophthalmic-drugs 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/lumithera-submits-de-novo-request-to-fda-for-valeda-light-delivery-system-for-the-treatment-of-dry-amd 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/ocuterra-marks-last-patient-s-final-visit-in-phase-2-dr-eam-study-of-nesvategrast-for-dr 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/fda-gives-its-blessing-to-ocuphire-pharma-s-special-protocol-assessment-for-lynx-2-phase-3-clinical-trial 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/splicebio-appoints-aniz-girach-as-chief-medical-officer 2024-01-04 0.50 https://www.ophthalmologytimes.com/view/alvotech-announces-positive-top-line-results-for-avt06-a-proposed-biosimilar-to-aflibercept 2024-01-03 0.50 https://www.ophthalmologytimes.com/view/retinalgenix-technologies-contracts-with-medsan-to-provide-diagnostic-testing-services 2024-01-02 0.50 https://www.ophthalmologytimes.com/view/ai-screens-for-autism-in-the-blink-of-an-eye 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/4dmt-receives-fda-regenerative-medicine-advanced-therapy-designation-for-4d-150-genetic-medicine-for-intravitreal-treatment-of-wet-amd 2024-01-02 0.50 https://www.ophthalmologytimes.com/view/ophthalmology-times-2023-wrapped 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/optometry-in-the-rearview-top-stories-from-optometry-times-in-2023 2024-01-02 0.50 https://www.ophthalmologytimes.com/view/looking-back-looking-forward-top-stories-from-ophthalmology-times-europe-2023 2023-12-21 0.50 https://www.ophthalmologytimes.com/view/5-top-stories-from-modern-retina-in-2023 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-zeroes-in-on-more-precise-and-flexible-targeted-spectroscopy-measurements-in-the-retina 2023-12-20 0.50 https://www.ophthalmologytimes.com/view/samsung-bioepis-receives-clinical-trial-suspension-for-violation-of-mfds-regulatory-requirements 2023-12-22 0.50 https://www.ophthalmologytimes.com/view/ocugen-receives-fda-alignment-on-key-points-of-phase-3-clinical-trial-design-for-ocu-400 2023-12-21 0.50 https://www.ophthalmologytimes.com/view/global-fluorescein-angiography-market-to-grow-considerably-by-2030 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-details-how-genes-in-retina-get-regulated-during-development 2023-12-18 0.50 https://www.ophthalmologytimes.com/view/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-diabetic-macular-edema 2023-12-20 0.50 https://www.ophthalmologytimes.com/view/fda-approves-travoprost-intracameral-implant 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-grants-rmat-designation-to-ocugen-s-ocu400-for-treatment-of-retinitis-pigmentosa-associated-with-rho-mutations 2023-12-19 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-offers-progress-report-in-odyssey-phase-2b-trial-of-cls-ax-in-wet-amd 2023-12-18 0.50 https://www.ophthalmologytimes.com/view/advancements-in-ophthalmology-a-comprehensive-look-at-the-fda-s-2023-approvals 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/carl-zeiss-meditec-ag-to-acquire-dutch-ophthalmic-research-center 2023-12-18 0.50 https://www.ophthalmologytimes.com/view/retina-fellows-forum-longest-running-retina-fellows-educational-opportunity 2023-12-18 0.50 https://www.ophthalmologytimes.com/view/retina-fellows-forum-awards-and-lecture-program 2023-12-14 0.50 https://www.ophthalmologytimes.com/view/dessislava-boneva-md-joins-retinalgenix-board-of-directors 2023-12-14 0.50 https://www.ophthalmologytimes.com/view/hkumed-achieves-breakthrough-in-photoactivatable-nanomedicine-for-the-treatment-of-age-related-macular-degeneration 2023-12-14 0.50 https://www.ophthalmologytimes.com/view/oct-retinal-scans-show-the-eye-kidney-connection 2023-12-14 0.50 https://www.ophthalmologytimes.com/view/ribomic-publishes-data-on-phase-1-and-phase-2-studies-of-umedaptanib-pegol-for-namd 2023-12-13 0.50 https://www.ophthalmologytimes.com/view/ocugen-doses-first-patient-in-phase-1-2-clinical-trial-evaluating-safety-efficacy-of-ocu410 2023-12-13 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-appoints-glenn-sblendorio-as-chairman-of-the-board 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/visgenx-extends-collaboration-with-charles-river-laboratories-to-manufacture-gene-therapy-treatment-for-amd 2023-12-12 0.50 https://www.ophthalmologytimes.com/view/effectiveness-of-pegcetacoplan-in-preserving-visual-function-in-geographic-atrophy 2023-12-12 0.50 https://www.ophthalmologytimes.com/view/efficacy-and-safety-of-pegcetacoplan-in-geographic-atrophy 2023-12-12 0.50 https://www.ophthalmologytimes.com/view/olix-pharmaceuticals-announces-positive-results-of-phase-1-study-of-safety-and-tolerability-of-olx10212 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/curing-genetic-blindness-with-space-enhanced-artificial-retinas 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/exn407-meets-endpoints-in-phase-ib-iia-trial-for-diabetic-macular-edema 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/harrow-completes-transfer-of-triesence-nda 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/cdr-life-inc-doses-first-patient-in-phase-1-trial-of-bi-771716 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/kubota-vision-announces-multiple-partnerships-around-its-eyemo-oct-device 2023-12-11 0.50 https://www.ophthalmologytimes.com/view/john-hopkins-researchers-explore-how-oxidative-stress-and-hif-1-proteins-contribute-to-amd-types 2023-12-08 0.50 https://www.ophthalmologytimes.com/view/predicting-intraocular-inflammation-after-intravitreous-brolucizumab-injections 2023-12-07 0.50 https://www.ophthalmologytimes.com/view/rheumatologic-ophthalmologic-teams-may-be-needed-to-improve-management-of-patients-with-rheumatic-diseases 2023-12-06 0.50 https://www.ophthalmologytimes.com/view/new-research-data-reflect-patient-satisfaction-following-faricimab-treat-and-extend-regimen 2023-12-06 0.50 https://www.ophthalmologytimes.com/view/study-fish-like-genetic-program-used-to-turn-human-retinal-cells-into-neurons 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-announces-positive-topline-data-from-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/atsena-therapeutics-announces-positive-12-month-safety-efficacy-data-from-phase-i-ii-clinical-trial-of-atsn-101 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/corza-medical-opens-its-ophthalmology-center-of-technology-and-innovation 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/subclinical-effects-of-anti-vegf-therapies-for-neovascular-amd 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-to-mark-geographic-atrophy-week 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/enzene-biosciences-launches-biosimilar-to-ranibizumab-for-treatment-of-neovascular-age-related-macular-degeneration-amd- 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/neuro-ophthalmic-adverse-events-associated-with-covid-19-infection-and-vaccinations 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-outlines-regulatory-path-forward-for-ons-5010 2023-11-29 0.50 https://www.ophthalmologytimes.com/view/incidence-of-syphilitic-uveitis-on-the-rise-in-the-us 2023-11-29 0.50 https://www.ophthalmologytimes.com/view/retinai-teams-up-with-stephen-j-ryan-initiative-for-macular-research-amd-consortium 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/zilia-receives-fda-clearance-for-retinal-camera 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/novel-3d-printed-device-may-offer-a-new-method-to-test-pharmaceuticals 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/in-israel-business-continues-amid-conflict 2023-11-28 0.50 https://www.ophthalmologytimes.com/view/navigating-disability-insurance-for-ophthalmologists-lessons-learned 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oculenz-headset-to-provide-those-with-advanced-macular-degeneration-with-enhanced-visual-clarity 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/eyecare-providers-report-slower-q3-and-increased-concern-for-the-us-economy-and-inflation-rates 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/rising-pollution-levels-in-delhi-trigger-40-surge-in-eye-problems 2023-11-28 0.50 https://www.ophthalmologytimes.com/view/aao-2023-real-world-outcomes-for-faricimab-for-amd 2023-11-27 0.50 https://www.ophthalmologytimes.com/view/aao-2023-avd-104-and-the-results-of-the-phase-ii-iii-part-1-siglec-trial 2023-11-20 0.50 https://www.ophthalmologytimes.com/view/aao-2023-centricity-vision-ceo-rob-thornhill-shares-company-updates 2023-11-28 0.50 https://www.ophthalmologytimes.com/view/kingfisher-study-safety-and-efficacy-of-brolucizumab-for-dme 2023-11-20 0.50 https://www.ophthalmologytimes.com/view/aao-2023-post-hoc-analysis-of-the-yosemite-and-rhine-clinical-trials 2023-11-20 0.50 https://www.ophthalmologytimes.com/view/editorial-cancer-and-the-eye-mysteries-remain 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/mass-eye-and-ear-researchers-create-possible-glaucoma-treatment-strategy-to-direct-stem-cells-to-retina 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/an-overview-of-the-paladin-study-for-diabetic-macular-edema-dme- 2023-11-22 0.50 https://www.ophthalmologytimes.com/view/aao-2023-results-of-the-photon-study-at-96-weeks 2023-11-20 0.50 https://www.ophthalmologytimes.com/view/tackling-visual-snow-syndrome-with-mindfulness-retraining-the-brain 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eyebio-announces-expansion-of-series-a-to-130-million-advances-development-of-restoret-for-retinal-diseases 2023-11-20 0.50 https://www.ophthalmologytimes.com/view/aao-2023-simplifying-the-charting-process-with-modmed-s-new-initiative 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oxurion-nv-will-file-for-bankruptcy-following-kalahari-data-release 2023-11-21 0.50 https://www.ophthalmologytimes.com/view/kilitch-healthcare-india-limited-issues-voluntary-recall-of-various-eye-drops-due-to-potential-safety-risk 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/cerebral-visual-impairment-documenting-the-visual-effects-and-simplifying-visual-life 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/former-uk-national-health-service-nhs-employee-found-guilty-for-illegally-accessing-medical-records 2023-11-20 0.50 https://www.ophthalmologytimes.com/view/fda-issues-warning-letter-to-amazon-for-selling-unapproved-eye-care-products 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-retinal-visualization-and-patients-who-ve-had-small-aperture-iol-implantation 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-the-gale-study-for-geographic-atrophy-management 2023-11-16 0.50 https://www.ophthalmologytimes.com/view/aao-2023-latest-diagnostic-and-therapeutic-advancements-in-ocular-infections 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/tarsier-pharma-holds-type-c-meeting-with-fda-for-trs01-in-noninfectious-uveitis 2023-11-16 0.50 https://www.ophthalmologytimes.com/view/study-the-role-of-iron-in-blindness-caused-by-ocular-toxoplasmosis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/medicines-and-healthcare-products-regulatory-agency-mhra-issues-uk-marketing-approval-for-biocon-biologics-biosimilar-aflibercept-yesafili- 2023-11-16 0.50 https://www.ophthalmologytimes.com/view/mco-010-optogenetic-gene-therapy-for-severe-vision-loss-in-stargardt-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/atsn-101-a-gene-therapy-for-gucy2d-associated-leber-congenital-amaurosis-has-demonstrated-clinically-meaningful-improvements-in-vision-at-the-highest-dose-with-no-drug-related-serious-adverse-events-6-months-post-treatment-in-ongoing-phase-i-ii-clinical-trial- 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aao-2023-norlase-4-years-later 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/leveling-the-playing-field-when-comparing-the-efficacy-of-pegcetacoplan-and-avacincaptad-pegol-in-patients-with-ga 2023-11-16 0.50 https://www.ophthalmologytimes.com/view/diabetic-eye-disease-news-from-around-the-world 2023-11-16 0.50 https://www.ophthalmologytimes.com/view/successful-treatment-of-bilateral-diffuse-uveal-melanocytic-proliueration-with-plasmapheresis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ema-recommends-approval-of-high-dose-intravitreal-aflibercept-eylea-8mg-for-namd-and-macular-edema 2023-11-13 0.50 https://www.ophthalmologytimes.com/view/akari-therapeutics-and-nanoscope-therapeutics-to-present-at-4th-annual-dry-amd-therapeutic-development-conference 2023-11-13 0.50 https://www.ophthalmologytimes.com/view/ocugen-doses-first-patient-in-phase-1-2-clinical-trial-evaluating-safety-efficacy-of-ocu410st-for-stargardt-disease 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/study-utah-researcher-validates-alternative-treatments-for-amd-disease 2023-11-10 0.50 https://www.ophthalmologytimes.com/view/aao-2023-cofi-company-updates-and-partnership-with-carecredit 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-updates-on-opthea-limited-shore-and-coast-clinical-trials 2023-11-10 0.50 https://www.ophthalmologytimes.com/view/cu-researcher-receives-grant-to-study-parkinson-s-disease-biomarkers 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aao-2023-neurotech-s-encapsulated-cell-therapy-nt-501 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/face-to-face-world-s-first-whole-eye-and-partial-face-transplant 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-paul-runge-and-his-rop-treatments-in-the-ukraine 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-sight-loss-in-working-age-people-is-under-researched 2023-11-08 0.50 https://www.ophthalmologytimes.com/view/aao-2023-children-with-sickle-cell-disease-suffer-from-eye-complications-at-the-same-rate-as-adults 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aao-2023-dr-caroline-baumal-discusses-the-pegcetacoplan-gale-extension-study-offers-leadership-insights 2023-11-10 0.50 https://www.ophthalmologytimes.com/view/ai-chatbots-produce-inaccurate-responses-for-eye-health-information 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-receives-cpt-category-1-code-for-triamcinolone-acetonide-injectable-suspension-xipere-from-american-medical-association 2023-11-08 0.50 https://www.ophthalmologytimes.com/view/amgen-confirms-fda-accepted-biologics-license-application-for-abp-938 2023-11-08 0.50 https://www.ophthalmologytimes.com/view/aao-2023-kiora-s-small-molecule-photoswitch-shows-meaningful-vision-improvements-in-blind-patients-diagnosed-with-rp 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aao-2023-iveric-bio-announces-positive-phase-3-results-for-avacincaptad-pegol-intravitreal-solution-for-ga-secondary-to-amd 2023-11-07 0.50 https://www.ophthalmologytimes.com/view/aao-2023-apellis-unveils-data-from-gale-extension-study 2023-11-06 0.50 https://www.ophthalmologytimes.com/view/aao-2023-visual-field-defects-linked-to-higher-risk-of-car-crashes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-the-bright-prospects-for-patients-with-dry-macular-degeneration 2023-10-30 0.50 https://www.ophthalmologytimes.com/view/kodiak-sciences-reboots-tarcocimab-tedromer-development-program-after-strong-positive-results-in-phase-3-glow-study 2023-11-06 0.50 https://www.ophthalmologytimes.com/view/learnings-from-real-world-evidence-of-faricimab-in-namd-and-dme-part-2 2023-11-06 0.50 https://www.ophthalmologytimes.com/view/learnings-from-real-world-evidence-of-faricimab-in-namd-and-dme-part-1 2023-11-06 0.50 https://www.ophthalmologytimes.com/view/aao-2023-tackling-the-physician-burnout-challenge-ophthalmologists-options 2023-10-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-adverum-biotechnologies-unveils-3-year-efficacy-safety-results-from-optic-extension-study-in-patients-with-wet-amd 2023-11-05 0.50 https://www.ophthalmologytimes.com/view/aao-2023-blindness-and-vision-loss-in-the-united-states-do-women-bear-a-greater-burden- 2023-11-02 0.50 https://www.ophthalmologytimes.com/view/aao-2023-ocuterra-s-ceo-shares-update-in-diabetic-retinopathy-treatment-study 2023-11-03 0.50 https://www.ophthalmologytimes.com/view/clinical-characteristics-and-progression-of-geographic-atrophy-in-a-japanese-population 2023-11-03 0.50 https://www.ophthalmologytimes.com/view/aao-2023-weight-loss-drug-does-not-appear-to-worsen-diabetic-eye-disease-in-most-patients 2023-11-03 0.50 https://www.ophthalmologytimes.com/view/aao-2023-shining-the-spotlight-on-advances-in-artificial-intelligence 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aao-2023-iris-registry-set-to-present-data-from-20-big-data-studies 2023-11-02 0.50 https://www.ophthalmologytimes.com/view/aao-2023-fundamentalvr-and-aao-team-up-for-pediatric-ophthalmic-training-vr-program 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aao-2023-pediatric-macular-holes-causes-characteristics-and-care 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/cost-effectiveness-analysis-of-pegcetacoplan-for-treating-ga 2023-10-31 0.50 https://www.ophthalmologytimes.com/view/aao-2023-oct-and-octa-longitudinal-study-further-highlights-macular-thickness-and-microvascular-changes-in-children-with-sickle-cell-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2023-two-rop-algorithm-simplifying-the-screening-process 2023-10-31 0.50 https://www.ophthalmologytimes.com/view/ocular-evaluations-recommended-for-patients-with-primary-vasculitis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/johnson-johnson-vision-focuses-on-barriers-faced-by-women-in-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-grants-toku-breakthrough-device-status-for-its-cardiovascular-risk-ai-platform 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-completes-recruitment-in-odyssey-phase-2b-clinical-trial-of-cls-ax-in-wet-amd 2023-11-02 0.50 https://www.ophthalmologytimes.com/view/setting-a-new-standard-in-automated-tracked-perimetry 2023-10-27 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-offers-informational-resources-to-ophthalmologists-for-diabetes-related-eye-disease-awareness-month 2023-10-27 0.50 https://www.ophthalmologytimes.com/view/aao-2023-museum-of-the-eye-a-can-t-miss-for-ophthalmologists 2023-10-27 0.50 https://www.ophthalmologytimes.com/view/study-pseudo-cell-formulation-targets-vitreoretinal-disease 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/fda-approves-faricimab-svoa-for-the-treatment-of-retinal-vein-occlusion 2024-02-01 0.50 https://www.ophthalmologytimes.com/view/visgenx-issued-patent-for-compositions-of-elovl2-gene-therapy 2023-10-25 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-rolls-out-new-surgical-planning-software-for-eyetelligence-platform 2023-10-25 0.50 https://www.ophthalmologytimes.com/view/harrow-completes-transfer-of-ndas-and-launches-5-products-in-the-us 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/companies-announce-their-upcoming-presentations-and-data-releases-for-the-american-academy-of-ophthalmology-aao-2023-meeting-in-san-francisco 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-grants-endogena-s-investigational-new-drug-application-for-ea-2351 2023-10-24 0.50 https://www.ophthalmologytimes.com/view/study-collaboration-across-disciplines-ensuring-fairness-of-ai-in-healthcare 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/enrollment-in-siglec-phase-2-3-us-clinical-trial-is-complete-aviceda-therapeutics-to-initiate-part-2 2023-10-23 0.50 https://www.ophthalmologytimes.com/view/phase-3-oaks-and-derby-studies-show-clinically-meaningful-reduction-in-ga-lesion-growth 2023-10-23 0.50 https://www.ophthalmologytimes.com/view/study-molecular-age-of-the-eye-determined-for-the-first-time 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-brings-on-new-board-member-and-promotes-new-executive-vice-president 2023-10-23 0.50 https://www.ophthalmologytimes.com/view/china-s-nmpa-approves-ind-application-for-skg0106-skyline-therapeutics-gene-therapy-for-neovascular-amd 2023-10-20 0.50 https://www.ophthalmologytimes.com/view/aao-2023-san-francisco-where-all-of-ophthalmology-meets- 2023-10-18 0.50 https://www.ophthalmologytimes.com/view/vitreous-retina-macula-consultants-of-new-york-vrmny-to-participate-in-a-wet-amd-study-with-regenxbio 2023-10-20 0.50 https://www.ophthalmologytimes.com/view/roche-halts-development-of-oral-vacasinabin-as-diabetic-retinopathy-treatment 2023-10-19 0.50 https://www.ophthalmologytimes.com/view/samsung-bioepis-presented-a-post-hoc-analysis-of-the-phase-3-clinical-study-results-for-sb15-at-euretina-2023 2023-10-17 0.50 https://www.ophthalmologytimes.com/view/diagnos-partners-with-coordinated-accessible-national-health-network-to-expand-ai-retinal-screening-across-canada 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/ranibizumab-eqrn-a-biosilimar-by-coherus-biosciences-exceeds-100-000-doses-in-first-year 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/conflict-in-israel-could-have-dire-impact-on-ophthalmic-care-in-country 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/avd-104-from-aviceda-shows-continued-clinical-safety-in-treatment-of-geographic-atrophy 2023-10-17 0.50 https://www.ophthalmologytimes.com/view/retina-society-2023-phase-3-studies-of-dual-inhibition-of-vegf-c-d-and-vegf-a-using-opt-302-in-combination-with-ranibizumab-or-aflibercept-in-neovascular-amd 2023-10-17 0.50 https://www.ophthalmologytimes.com/view/retina-society-2023-subgroup-analyses-of-phase-1-davio-trial-of-eyp-1901-demonstrating-reduced-treatment-burden-in-wet-amd 2023-10-18 0.50 https://www.ophthalmologytimes.com/view/retina-society-2023-a-comparison-of-the-antiangiogenic-profile-of-tyrosine-kinase-inhibitors-vorolanib-axitinib-and-sunitinib 2023-10-18 0.50 https://www.ophthalmologytimes.com/view/study-defective-emc1-protein-may-contribute-to-a-severe-ocular-disorder-familial-exudative-vitreoretinopathy 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/us-patent-and-trademark-office-issues-patent-to-lineage-cell-therapeutics-covering-ppoprietary-manufacturing-and-differentiation-process-for-rpe-cells 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/pegcetacoplan-injections-for-geographic-atrophy-associated-with-silicone-oil-drops-in-vitreous-cavity 2023-10-11 0.50 https://www.ophthalmologytimes.com/view/positive-phase-3-diamond-trial-results-for-ocs-01-in-dme-unveiled-at-euretina-congress 2023-10-12 0.50 https://www.ophthalmologytimes.com/view/experimental-study-of-evaporative-heavy-liquids-for-retinal-tamponade 2023-10-11 0.50 https://www.ophthalmologytimes.com/view/retina-society-2023-a-modified-endolaser-instrument-for-chandelier-scleral-buckle-procedures 2023-10-05 0.50 https://www.ophthalmologytimes.com/view/icter-researchers-achieve-potential-breakthrough-in-the-diagnosis-of-eye-diseases 2023-10-10 0.50 https://www.ophthalmologytimes.com/view/retina-society-2023-personalized-faricimab-dosing-shows-promise-in-extending-wet-amd-treatment-intervals- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/new-study-reveals-improved-eye-health-could-boost-us-economy-by-50-4-billion-annually 2023-10-11 0.50 https://www.ophthalmologytimes.com/view/the-us-food-and-drug-administration-releases-guidance-document-draft-for-quality-consideration-for-topical-ophthalmic-drug-products 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ophthalmologists-from-mount-sinai-to-present-research-at-the-56th-annual-retinal-society-scientific-meeting 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retina-society-2023-association-between-geographic-atrophy-and-meaningful-disease-burden-over-time 2023-10-02 0.50 https://www.ophthalmologytimes.com/view/faricimab-maintained-vision-improvements-with-extended-treatment-intervals-up-to-4-months-for-people-with-retinal-vein-occlusion-in-phase-iii-studies 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/retina-society-annual-congress-to-feature-insights-on-research-and-clinical-trials-from-alimera-sciences-nanoscope-therapeutics-and-ocuphire-pharma-among-presentations 2023-10-11 0.50 https://www.ophthalmologytimes.com/view/aao-returning-home-for-annual-meeting 2023-10-11 0.50 https://www.ophthalmologytimes.com/view/potential-bacterial-involvement-in-the-development-of-severe-rop 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/world-sight-day-2023-focusing-on-preservation-of-vision-in-the-workplace 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/case-series-finds-floaters-are-a-common-side-effect-of-syfovre 2023-10-10 0.50 https://www.ophthalmologytimes.com/view/innovent-doses-first-patient-in-phase-3-star-clinical-trial-for-namd 2023-10-10 0.50 https://www.ophthalmologytimes.com/view/euretina-2023-emerging-therapies-for-exudative-amd 2023-10-09 0.50 https://www.ophthalmologytimes.com/view/rg6501-phase-1-2a-results-show-evidence-of-improvement-of-outer-retinal-structure-in-patients-with-ga 2023-10-07 0.50 https://www.ophthalmologytimes.com/view/apellis-provides-update-on-cases-of-retinal-vasculitis-among-patients-treated-with-pegcetacoplan-injection 2023-10-07 0.50 https://www.ophthalmologytimes.com/view/arctic-vision-completes-enrollment-in-phase-3-trial-for-uveitic-macular-edema-treatment-arcatus 2023-10-05 0.50 https://www.ophthalmologytimes.com/view/ed-buffington-president-and-ceo-of-gpn-technologies-to-receive-2024-person-of-vision-award-from-prevent-blindness 2023-10-03 0.50 https://www.ophthalmologytimes.com/view/aflibercept-8-mg-for-dme-dosed-every-12-16-weeks-comparable-bcva-to-every-8-week-dosing 2023-09-27 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-announces-launch-of-pure-line-gases-for-retina-surgeons-ahead-of-euretina-annual-meeting 2023-10-05 0.50 https://www.ophthalmologytimes.com/view/euretina-2023-ali-erginay-md-discusses-advancements-in-ultra-widefield-imaging 2023-10-03 0.50 https://www.ophthalmologytimes.com/view/euretina-2023-safety-and-efficacy-through-week-48-in-the-phase-2a-starlight-clinical-trial 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/zeiss-medical-technology-and-boehringer-ingelheim-announce-long-term-collaboration 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/phase-3-pulsar-study-aflibercept-8-mg-monotherapy-for-pcv-robust-efficacy-benefits 2023-09-28 0.50 https://www.ophthalmologytimes.com/view/euretina-2023-the-real-world-efficacy-and-safety-of-faricimab-in-neovascular-amd-the-truckee-study 2023-10-05 0.50 https://www.ophthalmologytimes.com/view/espansione-group-shares-preliminary-results-from-lightwave-i-a-multicentric-randomized-controlled-investigation-of-lm-lllt-technology-for-dry-amd 2023-10-03 0.50 https://www.ophthalmologytimes.com/view/lead-study-reducing-amd-progression-rates-with-subthresold-nanosecond-laser-in-eyes-with-no-pseudo-drusen 2023-09-27 0.50 https://www.ophthalmologytimes.com/view/euretina-2023-varun-chaudhary-md-discusses-posturing-after-macular-hole-surgery 2023-10-02 0.50 https://www.ophthalmologytimes.com/view/beyond-the-bedroom-how-stis-are-affecting-vision-across-america 2023-10-03 0.50 https://www.ophthalmologytimes.com/view/nih-awards-researchers-1-2m-to-develop-robotic-eye-examination-system 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eye-health-what-should-patients-know- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-grants-510-k-clearance-to-altris-ims-platform 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/questions-in-ophthalmology-what-do-you-wish-patients-knew-about-eye-health- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/an-expert-opinion-what-do-you-wish-patients-knew-about-eye-health- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/proqr-therapeutics-offers-update-on-sale-of-ophthalmic-assets 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/humonix-biosciences-debuts-new-3d-human-tissue-model 2023-09-28 0.50 https://www.ophthalmologytimes.com/view/impact-of-disease-activity-criteria-on-dosing-interval-assignment-in-clinical-trials-in-namd 2023-09-28 0.50 https://www.ophthalmologytimes.com/view/kriya-announces-exclusive-license-collaboration-agreement-with-everads-to-advance-gene-therapies-for-diseases-in-ophthalmology-including-ga 2023-09-28 0.50 https://www.ophthalmologytimes.com/view/david-huang-md-phd-receives-lasker-award-for-transformative-imaging-technology 2023-09-28 0.50 https://www.ophthalmologytimes.com/view/patients-and-their-eye-health-experts-weigh-in 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-approves-ryzumvi-phentolamine-ophthalmic-solution-for-the-treatment-of-pharmacologically-induced-mydriasis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/what-do-you-wish-patients-knew-about-eye-health- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/apellis-receives-permanent-j-code-for-pegcetacoplan-injection 2023-09-26 0.50 https://www.ophthalmologytimes.com/view/world-retina-day-new-data-from-kiora-pharmaceuticals-shines-a-light-on-inherited-retinal-diseases 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-awards-900-000-to-mitochem-therapeutics-to-study-target-and-mechanism-of-action-in-retinal-degeneration-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/orbis-international-siloam-vision-unite-to-save-sight-of-premature-infants-using-artificial-intelligence 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/world-retina-day-iveric-bio-kicks-off-more-to-see-campaign-to-increase-patient-awareness-of-ga 2023-09-22 0.50 https://www.ophthalmologytimes.com/view/industry-sponsored-satellite-symposia-at-the-23rd-euretina-congress 2023-09-19 0.50 https://www.ophthalmologytimes.com/view/study-researchers-find-new-mechanisms-that-cause-blindness-opening-the-door-to-future-treatments 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/23rd-annual-euretina-congress-seeing-eye-to-eye-in-amsterdam 2023-09-19 0.50 https://www.ophthalmologytimes.com/view/precision-medicine-in-diabetic-macular-edema-expert-consensus-on-the-efficacy-and-safety-of-the-0-19-mg-fluocinolone-acetonide-implant 2023-10-05 0.50 https://www.ophthalmologytimes.com/view/iveric-bio-partnering-with-actor-eric-stonestreet-to-raise-awareness-of-geographic-atrophy 2023-09-22 0.50 https://www.ophthalmologytimes.com/view/editorial-welcome-to-the-metaverse 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-joins-world-sight-day-global-initiative-of-love-your-eyes-at-work- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/listening-to-the-heart-lessons-from-cardiology-in-remote-monitoring-and-ai 2023-09-13 0.50 https://www.ophthalmologytimes.com/view/iveric-bio-releases-24-month-topline-results-from-phase-3-study-of-avacincaptad-pegol-intravitreal-solution-izervay-for-geographic-atrophy 2023-09-19 0.50 https://www.ophthalmologytimes.com/view/retinalgenix-technologies-focuses-on-prevention-of-blindness-early-detection-of-multiple-systemic-diseases 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/snaps-eye-shield-creating-the-gold-standard-for-postoperative-ocular-protection 2023-09-13 0.50 https://www.ophthalmologytimes.com/view/trends-may-shift-amd-treatment-paradigm 2023-09-18 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-seeks-to-bring-awareness-to-eye-inflammation-with-inflammatory-eye-disease-ied-awareness-week 2023-09-18 0.50 https://www.ophthalmologytimes.com/view/gene-therapy-what-s-to-come- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/intravitreal-pegcetacoplan-for-retinal-tissue-preservation-in-patients-with-ga 2023-09-13 0.50 https://www.ophthalmologytimes.com/view/poll-most-anticipated-emerging-therapies-in-neovascular-amd-and-dme 2023-11-01 0.50 https://www.ophthalmologytimes.com/view/neovascular-amd-and-dme-therapies-5-quotes-from-retina-specialists 2023-09-16 0.50 https://www.ophthalmologytimes.com/view/combined-use-of-e-cigarettes-and-cigarettes-causes-severe-and-frequent-ocular-symptoms-in-adolescents-and-young-adults 2023-09-13 0.50 https://www.ophthalmologytimes.com/view/retfound-new-ai-model-to-detect-retinal-disease-biomarkers-developed-by-moorfields-eye-hospital 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/poll-what-are-the-biggest-challenges-in-dme-management- 2023-09-27 0.50 https://www.ophthalmologytimes.com/view/using-virtual-reality-mobility-testing-as-a-standardized-clinical-end-point-in-inherited-retinal-disorders 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/study-researchers-discover-a-key-failure-in-amd-that-may-lead-to-progression-and-vision-loss 2023-09-16 0.50 https://www.ophthalmologytimes.com/view/poll-exploring-the-dosing-intervals-of-faricimab-for-treating-neovascular-amd-in-the-clinical-practice-setting 2023-10-25 0.50 https://www.ophthalmologytimes.com/view/iapb-holding-2023-world-sight-day-photo-competition 2023-09-15 0.50 https://www.ophthalmologytimes.com/view/ocugen-announces-positive-clinical-study-update-from-the-phase-1-2-trial-of-ocu400 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/neovascular-amd-and-dme-therapies-10-top-takeaways-from-retina-specialists 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/owl-leadership-summit-2023-navigating-ophthalmic-leadership-challenges-and-embracing-diversity 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/syncona-announces-novartis-will-discontinue-development-of-gt005-for-geographic-atrophy 2023-09-13 0.50 https://www.ophthalmologytimes.com/view/alex-gorsky-joins-neurotech-s-board-as-lead-director 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/-conversations-video-podcast-launches-sixth-episode-discussing-dry-amd-and-ga 2023-09-11 0.50 https://www.ophthalmologytimes.com/view/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer 2023-09-11 0.50 https://www.ophthalmologytimes.com/view/the-fda-issues-warning-letters-to-8-companies-for-manufacturing-marketing-unapproved-ophthalmic-drug-products 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/stuart-therapeutics-announces-issuance-of-patent-covering-ophthalmic-anterior-segment-disorders 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-doses-first-patient-in-phase-1-2-trial-of-opgx-lca5-in-patients-diagnosed-with-lca5 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/orbis-and-heidelberg-engineering-announce-new-partnership 2023-09-11 0.50 https://www.ophthalmologytimes.com/view/otsuka-shapetx-collaborate-to-develop-novel-aav-gene-therapies-for-ocular-diseases 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/actress-debbie-allen-joins-prevent-blindness-regeneron-to-kick-off-the-gr8-eye-movement-to-raise-awareness-of-serious-retinal-diseases 2023-09-11 0.50 https://www.ophthalmologytimes.com/view/4dmt-first-patient-enrolled-in-4d-150-phase-2-spectra-pris-clinical-trials 2023-09-11 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-pharmaceutical-companies-scheduled-to-present-at-upcoming-investor-conferences 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/escrs-ace-vision-group-makes-presentations-focused-on-laser-scleral-microporation 2023-09-09 0.50 https://www.ophthalmologytimes.com/view/ophthalmologist-tapped-by-clinique-to-educate-consumers-on-eye-safety 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/pegcetacoplan-vs-avacincaptad-pegol-in-patients-with-geographic-atrophy 2023-09-08 0.50 https://www.ophthalmologytimes.com/view/oklahoma-s-dean-mcgee-eye-institute-dmei-to-begin-administering-luxturna-for-treatment-of-leber-congenital-amaurosis-lca- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/neurophth-gets-australian-approval-for-ophthalmic-gene-therapy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/bvi-expands-its-presence-in-europe-by-acquiring-medical-mix 2023-09-07 0.50 https://www.ophthalmologytimes.com/view/akari-therapeutics-establishes-boston-office-as-us-headquarters 2023-09-07 0.50 https://www.ophthalmologytimes.com/view/covid-19-treatment-changes-infant-s-eye-color 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eyesouth-partners-has-partnered-with-retina-and-vitreous-of-texas-in-houston 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/orbis-celebrates-20-years-of-cybersight-telemedicine-platform-new-app 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/uc-davis-researchers-administer-phase-3-abbv-rgx-314-a-gene-therapy-treatment-for-wet-amd 2023-09-05 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-attendees-share-the-topics-from-the-annual-meeting-that-interest-them 2023-08-31 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-our-team-asked-researchers-which-presentations-at-the-annual-asrs-meeting-they-find-most-interesting 2023-08-29 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-which-topics-at-the-annual-meeting-did-researchers-find-exciting- 2023-08-29 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-more-than-32-000-sports-related-eye-injuries-treated-in-2022-up-almost-20-percent-from-previous-year 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-presenters-share-what-research-at-the-2023-asrs-annual-meeting-they-find-exciting 2023-08-29 0.50 https://www.ophthalmologytimes.com/view/uc-irvine-researchers-discover-a-nanobody-which-may-lead-to-treatment-for-retinitis-pigmentosa 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-what-research-is-most-exciting-our-interviewees-weigh-in- 2023-08-29 0.50 https://www.ophthalmologytimes.com/view/usc-backed-startup-awarded-grant-for-clinical-trial-of-eye-treatment 2023-08-28 0.50 https://www.ophthalmologytimes.com/view/breaking-fda-issues-crl-for-outlook-therapeutics-ons-5010 2023-08-30 0.50 https://www.ophthalmologytimes.com/view/first-case-of-recurrent-multiple-evanescent-white-dot-syndrome-mewds-shown-in-woman-following-both-covid-19-vaccination-and-subsequent-infection 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/apellis-announces-corporate-restructuring-to-drive-growth-of-pegcetacoplan 2023-08-29 0.50 https://www.ophthalmologytimes.com/view/atsena-therapeutics-doses-first-patient-in-phase-i-ii-clinical-trial-of-atsn-201-for-treatment-of-x-linked-retinoschisis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/onl-therapeutics-completes-enrollment-in-study-of-first-in-class-fas-inhibitor-in-patients-diagnosed-with-macula-off-rhegmatogenous-retinal-detachment 2023-08-28 0.50 https://www.ophthalmologytimes.com/view/nei-awards-2-8-million-grant-to-wright-state-psychologist-for-eye-research 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/tarsier-pharma-shares-results-from-phase-3-trs4vision-trial 2023-08-28 0.50 https://www.ophthalmologytimes.com/view/the-retinal-degeneration-fund-announces-investment-in-amber-bio 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/wio-2023-zeta-1-phase-2-trial-safety-and-tolerability-results-for-apx3330 2023-08-24 0.50 https://www.ophthalmologytimes.com/view/wio-2023-the-current-landscape-of-geographic-atrophy 2023-08-28 0.50 https://www.ophthalmologytimes.com/view/new-developments-in-vitreoretinal-surgery-3d-viewing-systems-and-robotics-the-future-is-now 2023-08-28 0.50 https://www.ophthalmologytimes.com/view/wio-2023-robots-and-3d-surgery-what-is-the-future-and-surgical-retina- 2023-08-24 0.50 https://www.ophthalmologytimes.com/view/immunosuppressants-used-to-control-ocular-inflammation-not-involved-in-cancer-development 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-granted-us-and-european-patents-for-local-ocular-delivery-of-the-kio-100-family-of-compounds 2023-08-24 0.50 https://www.ophthalmologytimes.com/view/apellis-provides-an-update-on-rare-events-of-retinal-vasculitis-in-pegcetacoplan-injection 2023-08-24 0.50 https://www.ophthalmologytimes.com/view/study-scientists-develop-new-therapeutic-model-for-potentially-treating-incurable-eye-diseases 2023-08-23 0.50 https://www.ophthalmologytimes.com/view/ema-approves-clinical-trial-application-for-retinitis-pigmentosa-therapy-from-vigeneron 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/certain-inherited-retinal-diseases-are-characterized-by-large-cystoid-macular-lesions 2023-08-23 0.50 https://www.ophthalmologytimes.com/view/retina-biomarkers-identified-7-years-before-clinical-diagnosis-of-parkinson-s-disease 2023-08-21 0.50 https://www.ophthalmologytimes.com/view/research-on-the-noelin-family-of-secreted-proteins-may-shed-light-on-blinding-conditions 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-approves-regeneron-s-aflibercept-injection-8mg-for-treatment-of-dme-dr-wet-amd 2023-08-19 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-provides-an-update-on-phase-2-luna-trial-evaluating-ixoberogene-soroparvovec-for-wet-amd 2023-08-18 0.50 https://www.ophthalmologytimes.com/view/eyenovia-acquires-us-commercial-rights-to-app13007-from-formosa-pharmaceuticals 2023-08-17 0.50 https://www.ophthalmologytimes.com/view/ema-accepts-iveric-bio-s-marketing-authorization-application-for-avacincaptad-pegol-for-geographic-atrophy 2023-08-18 0.50 https://www.ophthalmologytimes.com/view/ai-generated-ophthalmic-references-and-abstracts-proceed-with-caution 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/macular-retinal-detachment-development-associated-with-myopic-foveoschisis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/sandoz-shares-positive-results-for-biosimilar-aflibercept-in-mylight-phase-3-study 2023-08-15 0.50 https://www.ophthalmologytimes.com/view/retina-cell-nanotechnology-breakthrough-could-help-treat-blindness 2023-08-14 0.50 https://www.ophthalmologytimes.com/view/orbis-international-releases-new-research-supporting-artificial-intelligence-ai-detection-of-diabetic-retinopathy 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/aflibercept-8-mg-data-shows-durable-vision-gains-at-extended-dosing-intervals-for-wet-amd 2023-08-14 0.50 https://www.ophthalmologytimes.com/view/abvc-biopharma-announces-approved-plan-for-pilot-good-manufacturing-practice-gmp-facility-to-produce-vitargus 2023-08-08 0.50 https://www.ophthalmologytimes.com/view/concern-over-unknown-long-term-effects-of-wildfire-smoke-on-our-eyes 2023-08-08 0.50 https://www.ophthalmologytimes.com/view/research-shows-early-vitrectomy-using-silicone-oil-tamponade-for-endophthalmitis-improves-vision 2023-08-08 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-insights-on-avd-104-a-sialic-acid-coated-nanoparticle-therapeutic-for-geographic-atrophy 2023-08-15 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-ocuterra-therapeutics-update-on-ott166-eye-drops 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/euclid-vision-founder-george-glady-passes-away-73-obituary-death 2023-08-10 0.50 https://www.ophthalmologytimes.com/view/first-investigational-eye-drop-for-front-and-back-of-the-eye-met-both-primary-endpoints-in-phase-3-optimize-trial 2023-08-08 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-zeta-1-phase-2-trial-efficacy-results-for-apx3330-with-david-lally-md 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/want-to-know-about-retinal-and-choroidal-vascular-parameters-in-patients-with-csc-look-to-their-nails 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/gene-therapy-company-intergalactic-therapeutics-announces-closing 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-long-term-outcomes-of-iop-lowering-medication-in-the-paladin-trial 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-and-the-choroideremia-research-foundation-partner-to-advance-novel-choroideremia-treatment 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-clinical-characteristics-of-macular-holes-that-close-without-surgery 2023-08-07 0.50 https://www.ophthalmologytimes.com/view/factors-affecting-the-age-of-onset-of-age-related-macular-edema-amd- 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/women-in-ophthalmology-wio-coming-to-marco-island-florida 2023-08-04 0.50 https://www.ophthalmologytimes.com/view/bascom-palmer-eye-ranked-1-in-ophthalmology-for-the-20th-year-in-a-row-by-us-news-world-report 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-michael-singer-md-provides-details-on-the-starlight-study-for-stargardt-disease 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/first-patient-enrolled-in-leopard-trial-for-osc-01-eye-drops-by-oculis-for-treatment-of-cystoid-macular-edema-cme- 2023-08-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-aleksandra-rachiskaya-md-shares-insights-on-fluid-control-with-faricimab-compared-to-aflibercept-in-recent-studies 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-world-leaders-owl-leadership-summit-to-host-meeting-to-promote-and-develop-diverse-leadership 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/fda-approves-iveric-bio-s-avacincaptad-pegol-intravitreal-solution-for-treatment-of-geographic-atrophy 2023-08-06 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-nancy-lurker-of-eyepoint-pharmaceuticals-provides-update-on-the-phase-1-davio-trial-of-eyp-1901 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/august-is-children-s-eye-health-and-safety-month 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-paul-hahn-md-phd-shares-insights-on-pegcetacoplan-versus-avacincaptad-pegol-in-patients-with-geographic-atrophy 2023-08-04 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-assistant-program-launched-by-innovative-allied-health-college 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-russ-trenary-president-and-ceo-at-outlook-therapeutics-shares-update-on-work-toward-fda-approval-for-bevacizumab 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-megan-baldwin-ceo-of-opthea-limited-shares-updates-on-sozinibercept 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/study-determines-female-ophthalmology-students-were-less-likely-to-ask-questions-during-grand-rounds 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-gale-extension-study-showed-increasing-beneficial-effects-for-syfovre-pegcetacoplan-injection-over-30-months 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-insights-on-aviceda-avd-104-for-the-treatment-of-geographic-atrophy-from-macular-degeneration 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-ursla-schmidt-erfurth-md-shares-updates-from-the-gale-extension-study- 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-modern-retina-board-member-fernando-arevalo-shares-insights-from-his-presentation-on-retinal-detachments-associated-to-retinoschisis 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-dante-pieramici-md-provides-update-on-opt-302-or-sozinibercept- 2023-08-02 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-intended-versus-actual-treatment-intervals-between-intravitreal-anti-vegf-injections-effects-of-treatment-delays 2023-07-24 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-insights-in-infrared-video-for-vitreous-opacities-with-shawn-kavoussi-md 2023-08-02 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-tracking-trends-in-secondary-iol-surgery-among-vitreoretinal-surgeons 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-insights-in-the-faretina-study-of-diabetic-macular-edema 2023-07-31 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-new-macgyver-inspired-endolaser-option-for-chandelier-assisted-scleral-buckles 2023-07-26 0.50 https://www.ophthalmologytimes.com/view/not-all-full-thickness-macular-holes-require-surgery-blunt-ocular-trauma-and-hole-size-may-merit-observation 2023-07-24 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-health-disparities-in-lapses-in-diabetic-retinopathy-care 2023-07-25 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-ga-in-spotlight-as-annexon-presents-archer-trial-results-highlighting-potential-of-anx007-as-a-differentiated-treatment-for-disease 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-apellis-offers-update-on-review-of-safety-events-with-pegcetacoplan-injection-for-geographic-atrophy 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-michael-ip-md-shares-perspective-of-the-2023-meeting-in-seattle 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-diana-do-md-shares-update-on-photon-study-for-diabetic-macular-edema 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-efficacy-safety-of-biosimilars-ranibizumab-nuna-and-ranibizumab-eqrn-in-clinical-use 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-aflibercept-8-mg-two-year-results-from-photon-trial-in-dme-highlighted 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-aaviate-interim-safety-study-6-month-results-underscore-treatment-safety-with-suprachoroidally-injected-abbv-rgx-314-for-namd 2023-07-25 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-clearside-biomedical-s-suprachoroidal-injection-platform-taking-stage-in-seattle 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-sharing-outcomes-and-clinical-features-predictive-of-fungal-endophthalmitis 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-gather-1-and-gather-2-clinical-trial-for-geographic-atrophy-results 2023-07-29 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-deep-learning-models-and-the-importance-of-training-from-imaging-datasets 2023-07-29 0.50 https://www.ophthalmologytimes.com/view/asrs-live-4dmt-presents-positive-interim-data-from-intravitreal-4d-150-phase-1-2-prism-clinical-trial-inwet-amd 2023-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-detecting-early-diabetic-retinopathy-using-oct-a-blood-flow-analysis 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-normalized-blood-flow-index-provides-biomarker-for-diabetic-retinopathy-detection 2023-07-24 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-the-evolution-of-treatments-for-dry-macular-degeneration 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/long-term-cognitive-outcomes-not-negatively-impacted-by-intravitreal-bevacizumab-for-rop 2023-08-03 0.50 https://www.ophthalmologytimes.com/view/asclepix-therapeutics-securesm-10-million-series-a-3-financing-to-advance-phase-1-2a-clinical-study-of-axt107-for-wet-amd 2023-07-27 0.50 https://www.ophthalmologytimes.com/view/applying-deep-learning-to-retinitis-pigmentosa-patients-to-estimate-visual-acuity 2023-07-27 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-ocuphire-pharma-to-share-results-from-the-zeta-1-phase-2-trial-evaluating-apx3330-in-diabetic-retinopathy 2023-07-27 0.50 https://www.ophthalmologytimes.com/view/oxurion-receives-upfront-payment-of-approximately-400-000-contributing-to-oxurion-s-investment-in-thr-149 2023-07-27 0.50 https://www.ophthalmologytimes.com/view/essex-bio-technology-announces-phase-1-2-clinical-trial-of-eb12-20145p-hlx04-o-is-complete 2023-07-27 0.50 https://www.ophthalmologytimes.com/view/opthea-announces-biologic-drug-candidate-opt-302-to-be-named-sozinibercept 2023-07-26 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-annexon-to-share-results-of-archer-phase-2-trial-for-the-treatment-of-geographic-atrophy 2023-07-26 0.50 https://www.ophthalmologytimes.com/view/belite-bio-concluded-enrollment-in-pivotal-global-phase-3-dragon-trial 2023-07-26 0.50 https://www.ophthalmologytimes.com/view/retinai-medical-ag-and-retina-consultants-of-america-rca-partner-to-develop-database-using-ai 2023-12-04 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-starts-enrollment-of-participants-in-its-odyssey-phase-2b-clinical-trial-of-cls-ax 2023-07-24 0.50 https://www.ophthalmologytimes.com/view/kodiak-sciences-shares-data-from-daylight-phase-3-study-for-wet-amd 2023-07-24 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-genentech-to-present-new-data-at-the-upcoming-annual-meeting 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/key-retreatment-decisions-in-the-clinical-trials-for-faricimab-in-namd 2023-07-21 0.50 https://www.ophthalmologytimes.com/view/impact-of-personalized-dosing-of-faricimab-on-treatment-outcomes-in-namd 2023-07-21 0.50 https://www.ophthalmologytimes.com/view/ocuterra-therapeutics-reaches-full-enrollment-in-phase-2-dr-eam-of-ott166-eye-drops-for-diabetic-retinopathy 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/aviceda-therapeutics-to-present-on-avd-104-at-asrs-2023-and-ois 2023-07-20 0.50 https://www.ophthalmologytimes.com/view/enrollment-complete-in-the-phase-2-dose-expansion-stage-of-the-prism-clinical-trial 2023-07-19 0.50 https://www.ophthalmologytimes.com/view/harrow-acquires-stanten-s-branded-ophthalmic-portfolio 2023-07-19 0.50